<DOC>
	<DOCNO>NCT00222235</DOCNO>
	<brief_summary>This study determine effectiveness treatment glycine d-cycloserine addition normal antipsychotic regimen improve negative symptom cognitive impairment patient schizophrenia .</brief_summary>
	<brief_title>Adjunctive Treatment Decreasing Symptoms Schizophrenia</brief_title>
	<detailed_description>A double-blind , placebo control clinical trial examine whether adjunctive treatment glycine d-cycloserine , compare placebo , improve negative symptom cognitive impairment patient schizophrenia remain normal antipsychotic regimen . Multicenter , randomize , double-blinded placebo control parallel-groups clinical trial design test hypothesis intervention ( glycine d-cycloserine ) intend increase glutamatergic activity action NMDA receptor reduce persistant negative symptom cognitive impairment patient schizophrenia schizoaffective disorder . After initial screen phase establish clinical stability eligibility , patient assign one three adjunctive treatment ( placebo , d-cycloserine glycine ) 16 week double-blind treatment . Patients remain stable dose antipsychotic therapy ( clozapine ) throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>diagnosis schizophrenia schizoaffective disorder stable , endure negative symptom certain level ( SANS &gt; 19 ) clinically stable , psychotic symptom measure BPRS 19 , anxiety/depression BPRS 15 extrapyramidal symptom measure SAS 9 stable antipsychotic regimen ( include clozapine ) alcohol substance dependence within last six month alcohol substance abuse within last month organic brain disorder medical condition whose pathology treatment could alter presentation treatment schizophrenia , include active tuberculosis tuberculosis treatment , kidney stone , uncontrolled diabetes mellitus Female participant could pregnant require use documented method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>negative symptom</keyword>
	<keyword>cognitive impairment</keyword>
</DOC>